newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London

  • Ascentage Pharma Group International (NASDAQ: AAPG, HKEX: 6855) announced that management will attend two investor conferences in London, United Kingdom.
  • The company will present at the UBS Global Biopharma Conference on Monday, November 16, 2026, from 4:40 p.m. to 5:10 p.m. GMT at the Rosewood London.
  • Ascentage Pharma will also present at the 2026 Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, from 9:00 a.m. to 9:25 a.m. GMT at The Waldorf Hilton.
  • Investors may schedule one-on-one meetings with management by contacting the respective conference representatives.
  • Ascentage Pharma is a global commercial-stage biopharmaceutical company focused on cancer therapies, including inhibitors targeting apoptotic pathways like Bcl-2 & MDM2-p53, next-generation kinase inhibitors, & protein degraders.
  • Olverembatinib is the company's first approved product, a third-generation BCR-ABL1 inhibitor approved in China for CML patients with T315I mutations or resistance to prior TKIs, & it is listed on the China National Reimbursement Drug List.
  • Registrational Phase III trials for Olverembatinib include POLARIS-2 for CML, POLARIS-1 for newly diagnosed Ph+ ALL, & POLARIS-3 for SDH-deficient GIST patients.
  • Lisaftoclax is the company's second approved product, a Bcl-2 inhibitor approved in China for adult CLL/SLL patients who received prior systemic therapy including BTK inhibitors.
  • Global registrational Phase III trials for Lisaftoclax include GLORA, GLORA-2, GLORA-3, & GLORA-4 studies targeting various hematologic malignancies.
  • The company maintains global intellectual property rights & partnerships with major pharmaceutical firms such as Takeda, AstraZeneca, Merck, Pfizer, & Innovent.
  • Ascentage Pharma collaborates with leading research institutions including the Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute, & the University of Michigan.
  • The press release includes forward-looking statements subject to risks outlined in SEC filings, including the 2025 Annual Report on Form 20-F & the 2019 IPO prospectus.
  • Investor relations contact information is provided for Sumedh Sunkaraneni of Ascentage Pharma & Brian Korb of astr partners.